This marks the first approval for WELIREG in the European Union (EU). WELIREG is now approved in over 30 countries for certain adult patients with previously treated advanced RCC and in more than ...

RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Commission (EC) has conditionally approved WELIREG ® ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Commission (EC) has conditionally approved WELIREG ® ...

Rahway: Merck, known as MSD outside of the United States and Canada, has received conditional approval from the European ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Commission (EC) has conditionally approved WELIREG® (belzutifan), Merck’s oral hypoxia ...

Lenvima/Welireg combination showed the highest ORR (46.9%) and CBR (59%) among treatment arms in advanced ccRCC patients. Median progression-free survival was longest in the Lenvima/Welireg arm at ...

This marks the first approval for WELIREG in the European Union (EU). WELIREG is now approved in over 30 countries for certain adult patients with previously treated advanced RCC and in more than 40 ...

Merck’s Welireg receives European approval for two indications: Rahway, New Jersey Wednesday, February 19, 2025, 10:00 Hrs [IST] Merck, known as MSD outside of the United States ...

Merck (NYSE:MRK) announced Tuesday that the European Commission approved its anti-cancer agent Welireg (belzutifan) as a treatment for two tumor conditions linked to kidneys. Accordingly ...

Gilead Sciences has defied analysts’ expectations by passing on its chance to license Arcus Biosciences’ potential rival to Merck & Co.’s kidney cancer drug Welireg. Gilead had the right to ...